Why did CDC pause testing for rabies and mpox?

CDC pauses certain rabies and mpox testing

The CDC has paused testing for rabies and mpox, removing those diseases from a list of tests the agency conducts for state and local health departments. The change raises concerns among experts because it arrives amid broader worries about staff reductions, with potential knock-on effects for surveillance and outbreak response.

What the pause means operationally

State and local public health labs often rely on federal support during unusual events or surges—especially for specialized or lower-incidence pathogens like rabies. Pausing federal testing can change the workflow for local departments by shifting responsibility to:

• other state or regional reference labs,
• commercial or alternative testing networks, or
• internal public health lab capacity.

Why experts worry

The core concern highlighted in the summaries is capacity. If staffing declines limit the CDC’s testing role, then public health teams may face delays or reduced ability to rapidly confirm cases during emerging threats.

What to watch next

Even without details on timelines, the key public health question is whether states can maintain timely diagnosis and confirmation through other routes. The impact would likely be most visible during:

• outbreaks,
• investigations of potential exposure clusters, and
• periods of increased clinical suspicion.

For readers, the development underscores that disease monitoring is not just about detection technology—it also depends on staffing and the distribution of testing responsibilities across jurisdictions.

As always, individuals should continue following public health guidance relevant to exposure prevention and, if applicable, vaccination recommendations.